Friday, 10 September 2021

Proactive Investors Interview: BioLargo says its PFAS water testing program has been met with 'impressive response' from customers

Source: Proactive Investors (https://ca.proactiveinvestors.com/companies/news/960057/biolargo-says-its-pfas-water-testing-program-has-been-met-with--impressive-response--from-customers-960057.html

BioLargo, Inc's Randy Moore and Tonya Chandler joined Proactive to speak about the group's new service testing customer water to detect per- and polyfluoroalkyl substances (PFAS) contamination levels.

The group say the program offers 'peace of mind and proof of concept' to customers who need PFAS water treatment solutions in the face of an uncertain and rapidly evolving technological and regulatory landscape. From there, BioLargo’s proprietary PFAS water treatment technology, the Aqueous Electrostatic Concentrator (AEC) is deployed.

Wednesday, 8 September 2021

BioLargo to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021

Westminster, CA – September 8, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The conference is being held virtually on September 13-15, 2021. 

President and CEO of BioLargo Dennis Calvert will present on the company's cleantech products and services, such as its newly launched PFAS Testing Program. Attendees will learn about BioLargo’s business strategy for becoming a major player in the emerging PFAS water treatment and remediation market.

Mr. Calvert’s presentation begins at 7:00 am Eastern Time on Monday, September 13, 2021, and will be available “on demand” for 90 days thereafter. 

You may register to view the presentation for no charge, at this link: https://journey.ct.events/view/8fc14545-db68-4397-90e6-45267377c156 

For additional information about the conference, visit www.hcwevents.com/annualconference



About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Thursday, 2 September 2021

BioLargo Launches PFAS Testing and Treatment System Selection Program

Westminster, CA – September 2, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it has launched a new service offering to test customer water to determine PFAS contamination levels and advise on appropriate treatment equipment options to meet federal, state and local regulatory requirements. The program offers peace of mind and proof of concept to customers who need PFAS water treatment solutions in the face of an uncertain and rapidly evolving technological and regulatory landscape.

Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that contaminate drinking water in thousands of sites in the United States. The Federal government, and many state governments, are tightening regulations due to mounting evidence about the impacts of PFAS chemicals on human health and their ubiquity in water throughout the developed world. Learn more at https://www.biolargoengineering.com/biolargo-answers-administrations-urgent-call-for-mitigation-of-pfas-forever-chemicals/.

BioLargo’s new PFAS Testing Program offers customers timely, accurate, and reliable testing of their water to determine, quantify, and qualify their PFAS contamination problem. Once contamination and water chemistry are characterized, BioLargo selects and optimizes appropriate water treatment equipment from a menu of different technologies that addresses the customer’s specific water chemistry and PFAS contamination makeup. The company then offers on-site piloting of the company’s own PFAS water treatment technology (the Aqueous Electrostatic Concentrator, or AEC). The AEC is a low-cost, low-waste, and sustainable solution for removing PFAS from water.

Customers can reach out to BioLargo engineers to schedule testing at https://www.biolargoengineering.com/biolargo-pfas-testing-program/.  

Randall Moore, President of BioLargo’s engineering division said, “With the launch of this new program, our engineers will be able to better serve municipalities that are struggling with having to close water wells due to PFAS contamination. Our AEC system reduces treatment costs because it generates only a fraction of the PFAS-laden waste compared to other treatment technologies like carbon filtration or ion exchange. No two water sources have the same underlying chemistry, and there are over 4,500 different PFAS compounds that can contaminate water. Thus, it is crucial to optimize treatment processes for each situation.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Wednesday, 25 August 2021

BioLargo’s Tonya Chandler to Present with Expert Panel at Sustain SoCal’s Water Solutions 6 Web Conference on August 26, 2021










Westminster, CA – August 25, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced its participation in Water Solutions 6, the sixth annual water innovation focused conference run by Sustain SoCal, a leading cleantech industry advocacy organization in Southern California (https://sustainsocal.org). The event takes place on August 26, 2021 from 1:30 pm to 5:00 pm Pacific Time.

BioLargo’s Director of Strategic Marketing and Business Development Tonya Chandler will be presenting about recent innovations in water treatment focused on per- and polyfluoroalkyl substances (PFAS), a class of water contaminants of emerging concerns. She will discuss BioLargo’s innovative technology that removes PFAS from water without creating significant PFAS-laden waste, and the company’s plans to offer other new PFAS-related services to customers.  

Water Solutions 6 (WS6) is a virtual-only conference focused on exploring real life strategies and innovations in conservation, reuse, desal, water quality and big data in Southern California and the surrounding region. BioLargo is a Title Sponsor for the event.

Registration for WS6 is open to the public. Followers of BioLargo can register for free using the promo code WS6BLGOCOMP. Register here: https://sustainsocal.org/events/event/water-solutions-6/

Distinguished speakers include:

  • Joaquin Esquivel, Chair State Water Resources Board, California Water Board
  • John Arena, Business Outreach Manager, Metropolitan Water District
  • Duane Cave, Director, Moulton Niguel Water District
  • Cristina Ahmadpour, President, Isle Inc
  • Michael Thomas, Capital Program Management Unit Manager, Metropolitan Water district
  • Don Bunts, Assistant General Manager, Santa Margarita Water District
  • Sepi Shirkhani, Associate Engineer, Engineering Services Group, Metropolitan Water District
  • Alexander Loucopoulos, Managing Director, Sciens Capital
  • Marc Serna, Assistant General Manager, South Coast Water District
  • Megan Plumlee, Research Director, Orange County Water District
  • Brian Probolsky, President, Moulton Niguel Water District
  • Lindsey Stuvick, Water Efficiency Manager, Moulton Niguel Water District
  • Mike Hwang, Process Engineer and Technologist, Jacobs
  • Tonya Chandler, Director of Strategic Marketing and Business Development, BioLargo, Inc.

Sponsors for the event include:

  • Metropolitan Water District of Southern California
  • Moulton Niguel Water District
  • South Coast Water District
  • Los Angeles Cleantech Incubator (LACI)
  • BioLargo

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Tuesday, 17 August 2021

BioLargo Second Quarterly Report of 2021 Highlights Progress of PFAS Treatment Business and Expanding Engineering Client Base

Westminster, CA – August 17, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its latest Quarterly Report on Form 10-Q with the SEC yesterday (www.biolargo.com/sec-filings). The company has summarized some of the most important points from the report below.

The company is holding an investor webcast on Tuesday, August 17, 2021, at 8:00 am Pacific / 11:00 am Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/42482   

Dennis P. Calvert, President and CEO of BioLargo said, “In the past quarter we made significant advances in the commercialization of our PFAS treatment technology, secured new engineering service contracts,  and advanced multiple new high-value business opportunities that have the potential to accelerate our company’s growth in the coming year.”

Financial highlights from the 10-Q:

  • Consolidated revenue for the three months ended June 30, 2021 was $464,000, an 11% increase compared to the second quarter of 2020.
  • Continued to reduce debt obligations, including the payoff of $406,000 in convertible debt due in August 2021 through the payment of cash and equity, as reported on Form 8-K filed May 19, 2021. Since December 31, 2019, the company has reduced its debt by over $4 million.
  • Other than debt owed by its partially owned subsidiary Clyra Medical Technologies, Inc., only Small Business Association and Paycheck Protection Program (PPP) loans totaling $464,000 ($314,000 of which has been applied for forgiveness), and $50,000 of fixed-price convertible debt (due in 2023) remain on BioLargo’s balance sheet.
  • Decreased net loss by 28% compared to the second quarter of 2020.

Commercial, operational, and R&D highlights:

  • BioLargo Engineering, Science & Technologies (BLEST) was notified of several important contract awards with the potential to increase the company’s operating cash flow and support the subsidiary’s role of commercializing BioLargo’s patented technologies. Together, the new contracts are worth more than $1.2 million in revenue, most of which will be earned over the next six months.
  • Began processing potential-client water with the company’s proprietary PFAS-removal water treatment system (called the “BioLargo AEC”) for a major municipality in Southern California and a federal government agency, with sights set on on-site pilots in the near future.  
  • Peer-reviewed paper published about the safety of water treated by BioLargo’s energy-efficient water treatment technology, the AOS. The paper concluded that the levels of disinfection by-products generated by the AOS were comparable to those found in ordinary tap water, bolstering the company’s claims that the AOS is a safe, effective water treatment system.
  • Advanced a series of commercial opportunities that include product distribution, partnerships, and projects that company management believes could each generate significant revenue. In each case the company is engaged in contract negotiations and will report more details in the future.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 11 August 2021

BioLargo Q2 2021 Earnings Results Webcast and Conference Call Tuesday, August 17, 2021 - 11:00 AM Eastern Time

Westminster, CA – August 11, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company to host investor webcast and conference call on Tuesday August 17, 2021, at 8:00 am PST / 11:00 am EST, open to the public. A webcast and conference call will be held to review the company’s financial results, discuss recent events, and conduct a question-and-answer session.

The webcast, accompanying presentation materials, and teleconference replay will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio video software.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/42482

Teleconference Domestic:

844-602-0380

Teleconference International:

862-298-0970

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Tuesday, August 17, 2022

Teleconference Replay Expiration:

Tuesday, August 31, 2021

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

42482

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.